Oral Biofilm Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Options (Antimicrobial Agents, Antiplaque Agents, Nanoparticles, Photodynamic Therapy, Cold Atmospheric Plasma, Herbal/Natural Products, and Others), By End Users (Hospitals and Clinics, Academic Institutes and Research Centers and Others) and Region

Oral Biofilm Therapeutics Market size was valued at US$ 612.4 million in 2023 and is anticipated to grow at a CAGR of 8.2% from 2024-2030. Oral biofilms are complex and dynamic communities of microorganisms that form on various surfaces within the human oral cavity, particularly on teeth and gums. Dental plaque is one of the most commonly forming biofilms in the oral cavity and appears as a slimy layer on the surface of the teeth.

The prevalence of oral diseases plays a pivotal role in driving the growth of the oral biofilm therapy market revenues. Oral diseases, such as dental caries (cavities) and periodontal diseases (gum diseases), implant-related infections, and oropharyngeal candidiasis are closely linked to the formation and persistence of oral biofilms on teeth and gums. As these conditions affect a significant portion of the global population, there is a substantial demand for effective therapeutic solutions to address them. Oral biofilm therapy offers targeted treatments designed to combat the microbial communities within biofilms, preventing and managing oral diseases. Moreover, the growth of the oral biofilm therapy market is significantly driven by the combined forces of growing awareness of oral health and advancements in dental research. Increasing awareness among the general population about the importance of oral hygiene, regular dental check-ups, and the role of oral biofilms in causing dental diseases has spurred demand for effective treatments. Concurrently, ongoing research in dentistry and microbiology has provided deeper insights into the complex nature of oral biofilms and their implications for oral health. These advancements have paved the way for the development of targeted and innovative therapeutic approaches to address oral biofilm-related conditions.

However, developing and gaining regulatory approval for new therapeutic agents can be a lengthy and costly process. Hence stringent regulatory requirements and costly treatment options can limit the growth of the oral biofilm therapy market. Meanwhile, rising healthcare investments can create significant opportunities for market development. Moreover, key market players are announcing innovative launches, strategic collaborations, and several acquisitions to further contribute to the market growth.

 Oral Biofilm Therapeutics Market Developments:        

• In May 2017, EMS launched its latest AIRFLOW® Prophylaxis Master air polishing system for guided biofilm therapy.